What OMEICOS Therapeutics does

OMEICOS Therapeutics GmbH is a privately held, clinical-stage biopharmaceutical company founded in June 2013 as a spin-off of the Max Delbrück Center for Molecular Medicine (MDC) in Berlin. The company develops first-in-class, orally available small molecule therapeutics based on metabolically stable synthetic analogues of omega-3 fatty acid-derived epoxyeicosanoids (17,18-EEQ). Its lead compound, OMT-28, targets the GPCR receptor S1PR1 to drive downstream activation of the mitochondrial sirtuins SIRT1 and SIRT3 within the AMPK/SIRT1/SIRT3/PGC1-alpha network, combining immunomodulation with mitochondrial protection — a dual mechanism differentiating OMT-28 from single-mechanism competitors.

The company's pipeline is oriented toward diseases of high unmet medical need: Primary Mitochondrial Disease (PMD), atrial fibrillation (AF), cardiovascular inflammation/Coronary Artery Disease, and ophthalmological disorders (wet AMD, diabetic retinopathy). OMT-28 has been evaluated in more than 220 individuals across Phase 1, Phase 2, and the PMD-OPTION study, with a positive Phase 2a PMD-OPTION readout announced in January 2026 and a potentially pivotal Phase 2b/3 study planned for H2 2026. Operations span Germany (Berlin headquarters), the United States (wholly-owned subsidiary OMEICOS Ophthalmics, Inc. in Cambridge, MA), and clinical trial sites in Italy and the Netherlands.

OMEICOS' business model is asset-development-driven and pre-revenue: the company finances operations through successive venture equity rounds (cumulative approximately EUR 40 million led by Vesalius Biocapital, Forbion, and Remiges) supplemented by non-dilutive grants (approximately EUR 6.5 million from BMBF and Investitionsbank Berlin). With 11–50 employees and no commercialized product, the company is explicitly preparing for late-stage development and commercialization through partnering or licensing transactions rather than building an in-house commercial organization.

Name

OMEICOS Therapeutics

Legal name

OMEICOS Therapeutics GmbH

Website

https://omeicos.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

OMEICOS Therapeutics is a Berlin-based, clinical-stage biopharmaceutical company developing orally available small molecule therapeutics (lead asset OMT-28) that activate S1PR1/SIRT1/SIRT3 pathways to treat primary mitochondrial disease, atrial fibrillation, cardiovascular inflammation, and ophthalmological disorders.

Ownership category

akta.pro rank

Product category

Cardiovascular and Mitochondrial Disease Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)

Keywords

• Small molecule therapeutics
• Clinical-stage biopharmaceuticals
• Mitochondrial disease treatment
• Cardiovascular drug development
• Epoxyeicosanoid analogues

Headquarters

HQ city

Berlin

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Revenue model

1. Pharmaceutical Drug Development and Commercialization: OMEICOS is a clinical-stage biopharmaceutical company developing first-in-class small molecule therapeutics for mitochondrial and inflammatory disorders. The company is advancing OMT-28 through clinical trials toward potential approval and commercialization. Current focus is on completing Phase 2b/3 development in Primary Mitochondrial Disease and exploring partnering opportunities for late-stage development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

OMEICOS Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class, orally available small molecule therapeutics (lead compound OMT-28) based on metabolically stable synthetic analogues of omega-3 fatty acid-derived epoxyeicosanoids. The lead candidate targets the S1PR1 receptor and activates mitochondrial sirtuins SIRT1/SIRT3, addressing Primary Mitochondrial Disease, atrial fibrillation, cardiovascular inflammation, and ophthalmological disorders. The company currently generates no product revenue, operating via equity financing and non-dilutive grants while preparing for late-stage clinical development and potential partnering.

Product overview

OMEICOS Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class small molecule therapeutics based on synthetic analogues of omega-3 fatty acid-derived epoxyeicosanoids. The company's core product is lead compound OMT-28, currently in Phase 2 clinical development for Primary Mitochondrial Disease and previously evaluated in atrial fibrillation. OMT-28 targets the GPCR receptor S1PR1 to activate the AMPK/SIRT1/SIRT3/PGC1-alpha axis, combining immunomodulation with mitochondrial protection. The company's proprietary compound library supports multiple therapeutic programs including cardiovascular, inflammatory, mitochondrial, and ophthalmological diseases. OMT-28 has demonstrated excellent safety across over 220 individuals and shown significant positive effects on inflammatory biomarkers (GDF-15, IL-6) and mitochondrial function.

Differentiator

Problem solved

Functional benefit

Products and services

• OMT-28 A first-in-class, orally available, once-daily small molecule therapeutic; a metabolically stable synthetic analog of the omega-3 fatty acid metabolite 17,18-EEQ. It is a biased modulator of GPCR receptor S1PR1 that drives downstream activation of mitochondrial sirtuins SIRT1 and SIRT3, combining immunomodulation with mitochondrial protection for the treatment of Primary Mitochondrial Disease (PMD), atrial fibrillation, and cardiovascular inflammation. Safety/tolerability has been evaluated in 220+ individuals with demonstrated biomarker effects on NAD+/NADH, GSH/GSSG, GDF-15, and IL-6.
• OMEICOS Compound Library A proprietary library of metabolically robust, orally available synthetic analogues of omega-3 fatty acid-derived epoxyeicosanoids developed using industry-leading knowledge of omega-3 fatty acid metabolism and biology. The library underpins OMEICOS' pipeline across cardiovascular, inflammatory, mitochondrial, and ophthalmological diseases and supports multiple therapeutic programs beyond OMT-28.
• OMT-28 for Ophthalmology Exploratory development of OMT-28 for severe ophthalmological disorders including wet age-related macular degeneration (wet AMD) and diabetic retinopathy. Oral administration has demonstrated comparable therapeutic effects to intravitreally applied anti-VEGF therapy in preclinical mouse models in reducing abnormal blood vessel formation and leakiness. Being advanced via the US subsidiary OMEICOS Ophthalmics, Inc.

Quantifiable outcome

• Over 60% response rate in PMD-OPTION study patients
• +5 more outcomes

Segments4 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered major and core.

• BiotronikmajorTechnology or Integration · 29 April 2019Berlin-based medical device specialist providing implantable cardiac monitors for the PROMISE-AF clinical study to accurately detect and monitor arrhythmias and assess AF burden in patients.
• University of Texas Southwestern Medical CentercoreStrategic or Co-development Partner · 1 March 2017Collaboration with Prof. John R. Falck who pioneered identification and chemical synthesis of CYP eicosanoids. Falck is Welch Distinguished Chair of Chemistry at UT Southwestern.
• Max Delbrück Center for Molecular Medicine (MDC)coreStrategic or Co-development Partner · 1 June 2013OMI ECOS was spun out of MDC in Berlin in June 2013 based on ground-breaking discoveries in omega-3 fatty acid metabolism by founders including Dr. Wolf-Hagen Schunck. Ongoing collaboration for research and clinical activities.

Scale indicators9 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Stealth BioTherapeutics: Clinical-stage biopharmaceutical company developing mitochondrial-targeted therapeutics, including elamipretide for primary mitochondrial disease and Barth syndrome. Directly comparable to OMEICOS in target indication (PMD) and mechanistic focus on mitochondrial bioenergetics.
• Khondrion: Netherlands-based clinical-stage company developing small-molecule mitochondrial therapeutics, with lead asset sonlicromanol in Phase 2b for mitochondrial disease. Closely comparable in indication, modality (small molecule), and stage to OMEICOS' OMT-28.
• Abliva AB (formerly NeuroVive Pharmaceutical): Sweden-based mitochondrial medicine company developing KL1333 and other compounds for primary mitochondrial disease. Comparable in indication, small-molecule modality, and clinical-stage development profile.
• Reneo Pharmaceuticals: Clinical-stage company developing mavodelpar (REN001) for primary mitochondrial myopathies and other mitochondrial disorders. Closely comparable in indication (PMD myopathy), small-molecule modality, and clinical-stage development.
• InCarda Therapeutics: Clinical-stage company developing an inhaled flecainide formulation for paroxysmal atrial fibrillation. Directly comparable to OMEICOS' previous AF development focus with OMT-28, though differentiated by route of administration.

Emerging players

• Cardurion Pharmaceuticals: Boston-based cardiovascular drug development company advancing therapies for heart failure, arrhythmias, and other cardiovascular diseases. Comparable in CV therapeutic focus, particularly overlapping with OMEICOS' atrial fibrillation and cardiovascular inflammation programs.

Broad incumbents

• PTC Therapeutics: Established commercial-stage rare disease company with multiple approved products for genetic and orphan disorders. Comparable as a larger rare disease specialty pharma, providing relevant M&A and partnership comparables for OMEICOS' orphan PMD strategy.
• BioMarin Pharmaceutical: Major rare disease biopharmaceutical company with a portfolio of approved enzyme replacement and gene therapies for ultra-rare conditions. Relevant comparable for orphan disease pricing, regulatory strategy, and M&A benchmark for OMEICOS.
• Genentech (Roche): Market leader in wet AMD through Lucentis and Susvimo, and developer of Vabysmo. Relevant comparable as the dominant incumbent in the ophthalmology indication OMEICOS is targeting with its oral anti-VEGF alternative approach.
• Regeneron Pharmaceuticals: Developer of Eylea (aflibercept), the market-leading anti-VEGF therapy for wet AMD and diabetic retinopathy. Directly comparable as the incumbent standard-of-care that OMEICOS' oral ophthalmology program would aim to disrupt.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/omeicos
• LinkedInlinkedin.com/company/10380807

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds6 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OMEICOS Therapeutics